NCT02477696 2026-03-27
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting
Acerta Pharma BV
AstraZeneca
Acerta Pharma BV
Acerta Pharma BV